Author: adamlaing

vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)

Posted on by adamlaing

vivoVerse cofounders Dr. Adela Ben-Yakar and Dr. Sudip Mondal have published an article in Nature Methods titled “Femtosecond laser microdissection for isolation of regenerating C. elegans neurons for single-cell RNA sequencing.” This publication from their work in the Ben-Yakar Group at the University of Texas at Austin showcases a novel and powerful fs-LM technique to isolate single cells from organisms or live mouse brain slices without Read more about vivoVerse cofounders publish single-cell isolation method using femtosecond laser microdissection (fs-LM)[…]

Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse

Posted on by adamlaing

The vivoVerse team recently attended the 2023 Society of Toxicology (SOT) Annual Meeting. It was a great time networking with people in the toxicology and safety testing industry. At ToxExpo, we were happily busy at our booth (Figure 2) spreading the word about our toxicology screening services using the alternative animal model C. elegans as Read more about Meeting report: A successful and enjoyable time at SOT2023 in Nashville for vivoVerse[…]

C. elegans as a Model for Rapid, Cost-Effective Toxicology Assessments

Posted on by adamlaing

Toxicology testing (often called “safety testing” or “product safety testing”) is an essential component of many industries, including the chemical industry, pharmaceuticals, and environmental science. It involves the evaluation of any potential health hazards posed by chemicals and other substances to humans, to other animals, and to the environment. This testing is performed during the Read more about C. elegans as a Model for Rapid, Cost-Effective Toxicology Assessments[…]

vivoVerse at the Society of Toxicology Annual Meeting in Nashville

Posted on by adamlaing

The 2023 Society of Toxicology (SOT) Annual Meeting is coming up this month, and we will be attending! The SOT Annual Meeting is one of the largest gatherings of toxicologists from around the world. We are excited to join the thousands of attendees and hundreds of exhibitors in exchanging knowledge, publishing research findings, and learning Read more about vivoVerse at the Society of Toxicology Annual Meeting in Nashville[…]

vivoVerse moves into new HQ

Posted on by adamlaing

vivoVerse (formerly operating as Newormics) has expanded its base of operations into a customized, newly refurbished space in Austin, Texas. The new headquarters comprises over 2400 square-foot of laboratory, office, and meeting space and is situated in the Balcones Office Park, just north of downtown and UT Austin. Here, we lead you on a quick Read more about vivoVerse moves into new HQ[…]

Newormics resumes operations

Posted on by adamlaing

Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have resumed operations in our lab and in our manufacturing facility as of August 1st. This means we can now be contacted for purchasing our vivoCube system, accessory kits, and for obtaining more vivoChips for your Read more about Newormics resumes operations[…]

The Fast Team Uses the Worm

Posted on by adamlaing

In a play on the adage “the early bird gets the worm”, Newormics describes how Perlara accelerated the search for a repurposed drug to treat an orphan disease using the microscopic soil worm, C. elegans.   Drug repurposing, once thought to be much less desirable than the development of new molecular entities for disease treatment, Read more about The Fast Team Uses the Worm[…]

vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office

Posted on by adamlaing

Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, TX. August 5, 2020 – vivoVerse (formerly operating as Newormics), a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering Read more about vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office[…]

vivoVerse awarded SBIR Phase II grant from the NIMH

Posted on by adamlaing

vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies. vivoVerse’s core focus is to facilitate the use of C. elegans as Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]